Acute plasma amylase increase after glucagon-like peptide-1 receptor agonist exenatide administration in Type 2 diabetes

MM Smits; L Tonneijck; MHA Muskiet; M Diamant; MHH Kramer; Djuna Cahen; DH van Raalte

doi:10.1111/dme.13160

Acute plasma amylase increase after glucagon-like peptide-1 receptor agonist exenatide administration in Type 2 diabetes

MM Smits
, L Tonneijck
, MHA Muskiet
, M Diamant
, MHH Kramer
, Djuna Cahen
, DH van Raalte

Gastroenterology & Hepatology

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

23 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	591-592
Number of pages	2
Journal	Diabetic Medicine
Volume	34
Issue number	4
DOIs	https://doi.org/10.1111/dme.13160
Publication status	Published - 2017

Research programs

EMC OR-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/dme.13160

REPUB_98624_OA.pdfFinal published version, 108 KB

http://hdl.handle.net/1765/98624

Cite this

@article{1c679f8b72c64fc487ae628f1bf1ed74,

title = "Acute plasma amylase increase after glucagon-like peptide-1 receptor agonist exenatide administration in Type 2 diabetes",

author = "MM Smits and L Tonneijck and MHA Muskiet and M Diamant and MHH Kramer and Djuna Cahen and \{van Raalte\}, DH",

year = "2017",

doi = "10.1111/dme.13160",

language = "Undefined/Unknown",

volume = "34",

pages = "591--592",

journal = "Diabetic Medicine",

issn = "0742-3071",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "4",

}

TY - JOUR

T1 - Acute plasma amylase increase after glucagon-like peptide-1 receptor agonist exenatide administration in Type 2 diabetes

AU - Smits, MM

AU - Tonneijck, L

AU - Muskiet, MHA

AU - Diamant, M

AU - Kramer, MHH

AU - Cahen, Djuna

AU - van Raalte, DH

PY - 2017

Y1 - 2017

U2 - 10.1111/dme.13160

DO - 10.1111/dme.13160

M3 - Article

C2 - 27278095

SN - 0742-3071

VL - 34

SP - 591

EP - 592

JO - Diabetic Medicine

JF - Diabetic Medicine

IS - 4

ER -